Sustainable Drug Discovery and Development with End-of-Life Yield (SUDDEN)

Public description of the goals at the beginning of the project

The ecological risks related to pharmaceutical emissions are an increasing concern both locally and globally. Hormonal and antibiotic residues are particularly harmful even at very low concentrations. Current societal transformations incl. urbanization, population growth and ageing, contribute to the accumulation of pharmaceuticals in the environment at an accelerated pace. The SUDDEN project tackles the environmental hazards and sustainability challenges related to drug manufacturing, consumption, and end-of-life. The project aims to enhance the benign-by-design drug discovery, bridge the gaps in the legal framework of global production chains of pharmaceuticals, redesign modern wastewater purification and reuse of the sewage sludge, and introduce circular economy models to pharmaceutical packaging materials with a view to developing a Life Cycle Impact Assessment model to drug products and supporting the economic growth of sustainable pharmaceutical industry and services in Finland.

More information

  • Consortium's website
  • Consortium PI Jari Yli-Kauhaluoma, Professor, University of Finland, firstname.lastname(at)helsinki.fi

Do you have questions or feedback for us?